Scientific advances in regenerative medicine continue to offer great promise in our attempts to tackle intractable diseases, including those presented by aging populations and, potentially, to reduce health care costs. These advances will be applicable worldwide. However, as noted in a recent editorial (Pera, 2020), there is still much to be done to involve hitherto underrepresented groups in their contribution to research and in ensuring that research studies collectively address therapeutic priorities and have the potential to benefit all patients.
In 2020, the InterAcademy Partnership (IAP), the global network of more than 140 academies of science, engineering, and medicine, constituted a working group on regenerative medicine to integrate perspectives from researchers worldwide on the opportunities and challenges in this field with the following objectives:
To use advances in research and development as rapidly as possible, safely and equitably, to provide new routes to patient benefit worldwide.
To support medical claims by robust and replicable evidence so that patients and the public are not misled.
This IAP work focused on stem cells for unmet medical needs but it is...
“I’m not a scarcity guy, I’m an abundance guy”
– Colossal co-founder and CEO Ben Lamm, The New Yorker, 4/14/25
Even the most casual consumers of news will have seen the run of recent headlines featuring the company Colossal Biosciences. On March 4, they announced with great fanfare the world’s first-ever woolly mice, as a first step toward creating a woolly mammoth. Then they topped that on April 7 by unveiling one...
China's most infamous scientist is attempting a comeback. He Jiankui, who went to jail for three years after claiming he had created the world's first genetically altered babies, says he remains...
By Kevin Davies, Genetic Engineering & Biotechnology News | 03.27.2025
Aggregated News
Around 2018–19, there was not a bigger science and ethical story than the debate over heritable human genome editing (HHGE) and the scandal over the “CRISPR babies.” The scientist, He Jiankui, who attempted to engineer the germline of human embryos...
WASHINGTON — Keith Joung knows better than a lot of people what, exactly, it might require to prove to regulators and patients that CRISPR could be safely used to alter the genome of a human embryo. If, of course, society...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.